Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133020 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL598026 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL3422180 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5133849 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL2819924 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL7908254 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5193445 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL15508929 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL22777078 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL29040489 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | LYCIA THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4359414-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | Lycia Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11891558-B2 | Solid foam comprising mesogenic ligand-functionalized nanoparticles and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4274619-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | Lycia Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11708530-B2 | Organic ligands for templatable mesoscale nanocapsules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2022272307-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272307-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-10994016-B2 | Graphene oxide mediated cellular delivery of gadolinium-labeled molecules | NORTHWESTERN UNIVERSITY (US) | 2021-05-04 | — | — | US | disclosed |
| US-10994016-B2 | Graphene oxide mediated cellular delivery of gadolinium-labeled molecules | NORTHWESTERN UNIVERSITY (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200239781-A1 | Solid Foam Comprising Mesogenic Ligand-Functionalized Nanoparticles and Methods of Making and Using the Same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| EP-0882716-B1 | PYRIDINECARBOXAMIDE DERIVATIVES | NISSHIN PHARMA INC (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6046201-A | Pyridinecarboxamide derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| EP-0882716-A1 | PYRIDINECARBOXAMIDE DERIVATIVES | Nisshin Flour Milling Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708530-B2 | Organic ligands for templatable mesoscale nanocapsules | EPCAM, L1CAM, ICOSLG | TDP1 4047/4885MAOA 2001/4885MAOB 2543/4885 |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | FOLR1, FOLR2, FOLH1 | TDP1 3224/4885MAOA 1402/4885MAOB 830/4885 |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | FOLR1, FOLR2, FOLH1 | TDP1 3224/4885MAOA 1402/4885MAOB 830/4885 |
| US-10994016-B2 | Graphene oxide mediated cellular delivery of gadolinium-labeled molecules | GZMB, GCG, GLMN | TDP1 4111/4885MAOA 2362/4885MAOB 1427/4885 |
| US-20170074859-A1 | Graphene Oxide Cellular Delivery of Hydrophilic Small Molecules | CD44, EPCAM, VIM | TDP1 4616/4885MAOA 2648/4885MAOB 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.